VERAXA is implementing FDA-aligned New Approach Methodologies NAMs across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The st
Why Is VRXAW (VRXAW) Stock Up Today?
Updated Nov 22, 2026 6:10 AM ET ยท Prev Close $0.02
Session Regime & Catalyst Assessment
68% Signal ConvictionVrxaw Advancing 15.28% on 0.78x Relative Volume
Vrxaw (Vrxaw) is advancing 15.28% (+$0.00) to $0.03 on 0.78x average session volume. Relative to benchmarks, VRXAW is outperforming the S&P 500 by +18.92%. 14-day RSI stands at 33.1, keeping momentum in a bearish regime.
VERAXA is implementing FDA-aligned New Approach Methodologies NAMs across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The st
Price ($0.03) trades relative to 20-day SMA ($0.04) and 50-day SMA ($0.07).
Market & Sector Relative Strength
VRXAW outperforming the S&P 500 by +18.92%Options Flow & Execution Desk
Recent VRXAW Catalyst Headlines
Verified WireLos Angeles, Ca - October 13, 2026 Newmediawire - Veraxa Biotech Nasdaq Vrxa , an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings va
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activityZURICH, Switzerland October 13, 2026 -- Veraxa Biotech A
Los Angeles, Ca - October 7, 2026 Newmediawire - Veraxa Biotech Nasdaq Vrxa , a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administrat
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.03 (session resistance) for directional breakout confirmation.
Technical Regime (VRXAW)
BEARISH MA TRENDAbout VRXAW
Get Instant VRXAW Catalyst Alerts
Receive an email alert when VRXAW triggers an unusual volume breakout, options sweep, or rating shift.
VRXAW Session & Catalyst FAQ
Why is VRXAW stock up today?
Vrxaw (Vrxaw) is advancing 15.28% (+$0.00) to $0.03 on 0.78x average session volume. Relative to benchmarks, VRXAW is outperforming the S&P 500 by +18.92%. 14-day RSI stands at 33.1, keeping momentum in a bearish regime.
Is VRXAW stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.78x relative volume (low participation). Our multi-factor model currently rates VRXAW as HOLD. Review full valuation, quality, and timing signals on the VRXAW Buy or Sell Decision Brief โ
What is VRXAW's intrinsic value and expected trading range?
At $0.03, VRXAW's modeled 1-to-3 session range is $0.03 โ $0.03, with a key inflection level at $0.03 (session resistance). Compare current price against multi-year cash flow projections in the VRXAW Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for VRXAW?
RSI at 33.1 reflects soft below-midline momentum. VRXAW trades at $0.03 relative to its 20-day SMA ($0.04) and 50-day SMA ($0.07), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.